Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C-Reference-Cited by-同舟云学术

Suboptimal SVR rates in African patients with atypical genotype 1 subtypes: Implications for global elimination of hepatitis C

Published:2019-12 Issue:6 Volume:71 Page:1099-1105
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Childs Kate,Davis Christopher,Cannon Mary,Montague Sarah^ORCID,Filipe Ana,Tong Lily^ORCID,Simmonds Peter^ORCID,Smith Donald,Thomson Emma C.,Dusheiko Geoff,Agarwal Kosh

Funder

Wellcome Trust

Medical Research Council

Publisher

Elsevier BV

Subject

Hepatology

Reference21 articles.

1. Global hepatitis report;Hutin,2017

2. New highly diverse hepatitis C strains detected in sub-Saharan Africa have unknown susceptibility to direct-acting antiviral treatments;Davis;Hepatology,2018

3. Hepatitis C and the absence of genomic data in low-income countries: a barrier on the road to elimination?;Niebel;Lancet Gastroenterol Hepatol,2017

4. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource;Smith;Hepatology,2014

5. NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome;Zeuzem;J Hepatol,2017

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bemnifosbuvir (BEM, AT-527), a novel nucleotide analogue inhibitor of the hepatitis C virus NS5B polymerase;Expert Opinion on Investigational Drugs;2024-01-24

2. Genetic history of hepatitis C virus genotype 6 in Taiwan;Journal of the Formosan Medical Association;2023-11

3. Molecular characterization of patients with chronic hepatitis C virus infection in Jordan: implications on response to direct-acting antiviral therapy;International Journal of Infectious Diseases;2023-10

4. Current Hepatitis C Vaccine Candidates Based on the Induction of Neutralizing Antibodies;Viruses;2023-05-11

5. Therapeutic preparedness: DAA-resistant HCV variants in vitro and in vivo;Hepatology;2023-04-15